Skip to main content

Table 3 Meta-regression analyses for MACE and net clinical benefit

From: Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials

  MACE Net clinical benefit
  p Adj-R2 (%) I2 (%) Tau2 p Adj-R2 (%) I2 (%) Tau2
Percentage of ACS 0.028 7.59 54.65 0.3979 0.211 0 54.62 0.4356
Age 0.229 0 70.27 0.456 0.195 8.99 50.75 0.2937
Verifynow cutoff value 0.566 0 22.14 0 0.864 0 20.59 0.1935
Study size 0.005 44.13 46.13 0.2406 0.032 4.91 66.22 0.3069
Follow up 0.077 22.45 60.23 0.3181 0.022 61.72 40.97 0.1219
Intervention duration 0.005 76.06 36.87 0.09818 0.006 86.69 18.98 0.04239